FI118918B - Användningen av en CD40-reseptorbindar vid framställning av ett läkemedel - Google Patents

Användningen av en CD40-reseptorbindar vid framställning av ett läkemedel Download PDF

Info

Publication number
FI118918B
FI118918B FI972484A FI972484A FI118918B FI 118918 B FI118918 B FI 118918B FI 972484 A FI972484 A FI 972484A FI 972484 A FI972484 A FI 972484A FI 118918 B FI118918 B FI 118918B
Authority
FI
Finland
Prior art keywords
cell
cells
mab
cd40l
effect
Prior art date
Application number
FI972484A
Other languages
English (en)
Finnish (fi)
Other versions
FI972484A0 (sv
FI972484A (sv
Inventor
Lawrence Sterling Young
Original Assignee
Univ Birmingham
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Birmingham filed Critical Univ Birmingham
Publication of FI972484A0 publication Critical patent/FI972484A0/sv
Publication of FI972484A publication Critical patent/FI972484A/sv
Application granted granted Critical
Publication of FI118918B publication Critical patent/FI118918B/sv

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)

Claims (6)

1. Användningen av en CD40-reseptorbindare för framställning av ett läkeme-del för förebyggande av epitelcellers förökning eller för behandling av kancer i 5 epitelcellssystemen.
2. Användningen av en CD40-reseptorbindare för framställning av ett läkeme-del för förstärkning av neoplastiska epitelcellers mottaglighet för anti-neoplas-tisk läkemedelsinducerad apoptos. 10
3. Användningen av en CD40-reseptorbindare enligt patentkravet 1 tillsam-mans med ett CD40-induktionsmedel.
4. Användningen av en CD40-reseptorbindare enligt patentkravet 1 tillsam-15 mans med anti-neoplastiskt läkemedel.
5. Användningen enligt nägot av patentkraven 1-4, kännetecknad därav, att CD40-reseptorbindaren är vald bland ligandliknande monoklonala anti-kroppar och naturligt förekommande eller konstruerade former av CD40-ligander. »·»· 20 • · « • * 4t;j·
6. Användningen enligt nägot av patentkraven 1-4, kännetecknad därav, att !/.{ CD40-reseptorbindaren är vald bland G28.5 (deponeringsnummer HB-9110 (ATTC)) och CD40L. ··· • ♦ « ·.· · ·♦ • · • ·* ··· • · • · ··« ··· : : ··« • · ·» · • · e • * • · · ·♦·
FI972484A 1994-12-13 1997-06-12 Användningen av en CD40-reseptorbindar vid framställning av ett läkemedel FI118918B (sv)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB9425060 1994-12-13
GBGB9425060.2A GB9425060D0 (en) 1994-12-13 1994-12-13 Carcinoma treatment
PCT/GB1995/002807 WO1996018413A1 (en) 1994-12-13 1995-12-01 Carcinoma treatment
GB9502807 1995-12-01

Publications (3)

Publication Number Publication Date
FI972484A0 FI972484A0 (sv) 1997-06-12
FI972484A FI972484A (sv) 1997-06-12
FI118918B true FI118918B (sv) 2008-05-15

Family

ID=10765814

Family Applications (1)

Application Number Title Priority Date Filing Date
FI972484A FI118918B (sv) 1994-12-13 1997-06-12 Användningen av en CD40-reseptorbindar vid framställning av ett läkemedel

Country Status (12)

Country Link
EP (1) EP0806963B1 (sv)
JP (1) JP4076230B2 (sv)
AT (1) ATE203676T1 (sv)
AU (1) AU691996B2 (sv)
CA (1) CA2207779C (sv)
DE (1) DE69522012T2 (sv)
FI (1) FI118918B (sv)
GB (1) GB9425060D0 (sv)
MX (1) MX9704372A (sv)
NO (1) NO318587B1 (sv)
NZ (1) NZ296161A (sv)
WO (1) WO1996018413A1 (sv)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09507074A (ja) * 1993-12-23 1997-07-15 イミュネックス・コーポレーション Ｃｄ４０を発現する腫瘍細胞を特徴とする疾患の予防又は治療方法
US7070771B1 (en) * 1996-12-09 2006-07-04 Regents Of The University Of California Methods of expressing chimeric mouse and human CD40 ligand in human CD40+ cells
EP1946775A3 (en) * 1998-08-11 2008-08-06 Biogen Idec Inc. Combination therapies for B-cell lymphomas comprising administration of anti-CD20 antibody
US6946129B1 (en) 1999-06-08 2005-09-20 Seattle Genetics, Inc. Recombinant anti-CD40 antibody and uses thereof
US8557244B1 (en) 1999-08-11 2013-10-15 Biogen Idec Inc. Treatment of aggressive non-Hodgkins lymphoma with anti-CD20 antibody
US7138379B2 (en) * 2000-07-26 2006-11-21 Schering Aktiengesellschaft Use of the interferon receptor 2c polypeptide chain to enhance the anti-growth effects of type I interferons
GB0025132D0 (en) * 2000-10-13 2000-11-29 Medical Res Council Method
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
US7786282B2 (en) 2001-12-06 2010-08-31 The Regents Of The University Of California Nucleic acid molecules encoding TNF-α ligand polypeptides having a CD154 domain
US7495090B2 (en) 2002-05-23 2009-02-24 The Regents Of The University Of California Nucleic acids encoding chimeric CD154 polypeptides
EP1680141B8 (en) * 2003-11-04 2011-01-12 Novartis Vaccines and Diagnostics, Inc. Methods of therapy for solid tumors expressing the cd40 cell-surface antigen
US8277810B2 (en) 2003-11-04 2012-10-02 Novartis Vaccines & Diagnostics, Inc. Antagonist anti-CD40 antibodies
US20050136055A1 (en) 2003-12-22 2005-06-23 Pfizer Inc CD40 antibody formulation and methods
AU2006249305B2 (en) 2005-05-26 2012-10-18 Genentech, Inc. Humanized anti-CD40 antibodies and their methods of use
AU2006308606C1 (en) 2005-11-01 2013-07-25 Novartis Ag Uses of anti-CD40 antibodies
WO2007067032A1 (en) 2005-12-09 2007-06-14 Academisch Medisch Cemtrum Bij De Universiteit Van Amsterdam Means and methods for influencing the stability of cells
CA2633157C (en) 2005-12-09 2018-10-09 Academisch Medisch Centrum Bij De Universiteit Van Amsterdam Means and methods for influencing the stability of antibody producing cells
NZ571757A (en) 2006-04-21 2012-01-12 Novartis Ag Antagonist anti-CD40 antibody pharmaceutical compositions comprising arginine-HCl and a citrate or citric acid buffer
WO2009062125A1 (en) 2007-11-07 2009-05-14 Genentech, Inc. Methods and compositions for assessing responsiveness of b-cell lymphoma to treatment with anti-cd40 antibodies
AU2010236168B2 (en) 2009-04-18 2015-08-13 Genentech, Inc. Methods for assessing responsiveness of B-cell lymphoma to treatment with anti-CD40 antibodies
EP2454283B1 (en) 2009-07-15 2018-03-14 AIMM Therapeutics B.V. Means and methods for producing high affinity antibodies
AR083847A1 (es) 2010-11-15 2013-03-27 Novartis Ag Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
NZ611600A (en) 2010-12-02 2015-02-27 Aimm Therapeutics Bv Means and methods for producing high affinity antibodies
WO2012149356A2 (en) 2011-04-29 2012-11-01 Apexigen, Inc. Anti-cd40 antibodies and methods of use
EP3925977A1 (en) 2012-10-30 2021-12-22 Apexigen, Inc. Anti-cd40 antibodies and methods of use
DK3099709T3 (da) 2014-01-31 2020-02-03 Aimm Therapeutics Bv Midler og fremgangsmåder til fremstilling af stabile antistoffer

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5540926A (en) * 1992-09-04 1996-07-30 Bristol-Myers Squibb Company Soluble and its use in B cell stimulation

Also Published As

Publication number Publication date
WO1996018413A1 (en) 1996-06-20
CA2207779C (en) 2009-10-06
JPH10510526A (ja) 1998-10-13
NO972732L (no) 1997-06-13
DE69522012T2 (de) 2002-04-25
NO318587B1 (no) 2005-04-11
DE69522012D1 (de) 2001-09-06
JP4076230B2 (ja) 2008-04-16
AU691996B2 (en) 1998-05-28
EP0806963B1 (en) 2001-08-01
CA2207779A1 (en) 1996-06-20
FI972484A0 (sv) 1997-06-12
MX9704372A (es) 1998-02-28
FI972484A (sv) 1997-06-12
ATE203676T1 (de) 2001-08-15
GB9425060D0 (en) 1995-02-08
AU3988495A (en) 1996-07-03
EP0806963A1 (en) 1997-11-19
NO972732D0 (no) 1997-06-13
NZ296161A (en) 2001-10-26

Similar Documents

Publication Publication Date Title
FI118918B (sv) Användningen av en CD40-reseptorbindar vid framställning av ett läkemedel
EP2558075B1 (en) Compositions comprising polyglutamic acid nanoparticles and polypeptides such as cd40 agonists
Klimp et al. A potential role of macrophage activation in the treatment of cancer
Fransen et al. Local activation of CD8 T cells and systemic tumor eradication without toxicity via slow release and local delivery of agonistic CD40 antibody
US20230201305A9 (en) Immune checkpoint inhibitor combinations
AU2016201190A1 (en) Methods for enhancing anti-tumor antibody therapy
AU2005266543B2 (en) Tumor-homing cells engineered to produce tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)
LT4225B (en) Immuno-stimulatory monoclonal antibodies
MXPA96003080A (en) Monoclonal antibodies immuno-estimulan
Jazirehi et al. Epigenetic regulation of the TRAIL/Apo2L apoptotic pathway by histone deacetylase inhibitors: an attractive approach to bypass melanoma immunotherapy resistance
CN116916960A (zh) PPAR-delta抑制剂联合免疫治疗药物在制备抗肿瘤药物中的应用
KR20200030337A (ko) 종양 치료를 위한 항-cd 19 항체 및 자연살해세포를 포함하는 약학적 조합물
CN117050177B (zh) 血液分离的免疫细胞联合药物治疗癌症的用途
KR20210038447A (ko) 종양 치료를 위한 항-cd 19 항체 및 자연살해세포를 포함하는 약학적 조합물

Legal Events

Date Code Title Description
FG Patent granted

Ref document number: 118918

Country of ref document: FI